Oncolytic Virus Cancer Therapy Market

Key Findings:

 

  • In 2021, the total Oncolytic Virus Therapies market size was approximately USD 122 million which is expected to rise during the study period (2019–2032).
  • In 2021, the total Oncolytic Virus Therapies target patient pool cases across 7MM were about 632 K which are expected to grow during the study period, i.e., 2019–2032.

 

Request a sample to unlock the CAGR for Oncolytic Virus Therapies Market.

 

DelveInsight's "Oncolytic Virus Therapies- Market Insight, Epidemiology and Market Forecast Forecast-2032" report delivers an in-depth understanding of the Oncolytic Virus Therapies, historical and forecasted epidemiology as well as the Oncolytic Virus Therapies trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

The Oncolytic Virus Therapies market report provides emerging drugs, Oncolytic Virus Therapies market share of the individual cancer types, current and forecasted Oncolytic Virus Therapies market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Oncolytic Virus Therapies unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Oncolytic Virus Therapies Understanding and Treatment Algorithm

The DelveInsight’s Oncolytic Virus Therapies epidemiology report gives a thorough understanding of Oncolytic Virus Therapies by including details such as overview of Oncolytic Virus Therapies, advantages, disadvantages and available therapies. Comprehensive epidemiology insight of the tumors targeted by Oncolytic Virus Therapies. Oncolytic viruses (OVs), considered an effective anticancer strategy in recent years, are a special type of virus that are naturally or genetically engineered and can replicate preferentially in tumor cells and inhibit tumor growth. Oncolytic Virus Therapies is a treatment using a virus that can replicate itself to kill cancer cells. Many species of viruses exist, but not all can be designed to be oncolytic viruses (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity to be transformed to express tumor-killing factors through genetic engineering methods.

 

OVs have proven to be a powerful anticancer molecule, being able to be used for cancer diagnosis as well as treatment. Their multifunctional characteristics indicate good application prospects as cancer therapeutics, especially in combination with other therapies, such as radiotherapy, chemotherapy, and immunotherapy. Currently, only two oncolytic virus therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US and Europe in 2015, and DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) approved in Japan in 2021.

Oncolytic Virus Therapies Epidemiology

The epidemiology section provides the insights about historical and current indication wise eligible patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Oncolytic Virus Therapies Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Oncolytic Virus Therapies epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

In 2021, the total Oncolytic Virus Therapies target patient pool cases across 7MM were about 632 K which are expected to grow during the study period, i.e., 2019–2032.

 

The Oncolytic Virus Therapies epidemiology covered in the report provides historical as well as forecasted intratumoral cancer therapies epidemiology [segmented as Total Incident cases of selected cancer types (Melanoma, Nonmelanoma skin cancer, Pancreatic Cancer, Renal cell carcinoma, Prostate Cancer, Brain Cancer, Bladder cancer, and Ovarian cancer), Target patient Pool of intratumoral therapies by Cancer Types and Treated cases by Cancer Types] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

 

Country Wise- Oncolytic Virus Therapies Epidemiology

The epidemiology segment also provides the Oncolytic Virus Therapies epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Oncolytic Virus Cancer Prevalence

Oncolytic Virus Therapies Drug Chapters

The drug chapter segment of the Oncolytic Virus Therapies report encloses the detailed analysis of Oncolytic Virus Therapies marketed drugs and late stage (Phase III and Phase II) pipeline drugs. It also helps to understand the Oncolytic Virus Therapies clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Oncolytic Virus Emerging Drugs

The report provides the details of the emerging Oncolytic Virus Therapies under the late and mid-stage of development for selected indications treatment.

Oncolytic Virus Therapies Market Outlook

The Oncolytic Virus Therapies market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Oncolytic Virus Therapies market trends by analyzing the impact of current therapies on the market, unmet needs, and demand of better technology.

 

This segment gives a thorough detail of Oncolytic Virus Therapies market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Oncolytic Virus Therapies market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Oncolytic Virus Cancer Therapy Market

 

Oncolytic Virus Therapies Key Findings

The Oncolytic Virus Therapies market size in the 7MM is expected to change during the study period 2019–2032. The Oncolytic Virus therapeutic market in the seven major markets is expected to increase during the study period (2019–2032).

In 2021, the total Oncolytic Virus Therapies market size was approximately USD 122 million which is expected to rise during the study period (2019–2032).

 

The United States: Oncolytic Virus Therapies Market Outlook

The total Oncolytic Virus Therapies market size in the United States accounted for USD 84 million in 2021 which is expected to rise during the study period (2019–2032).

 

EU-5 Countries: Oncolytic Virus Therapies Market Outlook

In EU5, the total Oncolytic Virus Therapies market size was about USD 38 million in 2021, which is expected to rise during the study period (2019–2032).

 

Japan: Oncolytic Virus Therapies Market Outlook

In Japan, the total Oncolytic Virus Therapies market size was USD 0.01 million in 2021, which is expected to rise during the study period (2019–2032).

Oncolytic Virus Therapies Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Oncolytic Virus Therapies market or expected to get launched in the market during the study period 2019-2032. The analysis covers Oncolytic Virus Therapies market uptake by drugs; patient uptake by therapies; and sales of each drug.  

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Oncolytic Virus Therapies Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key players involved in developing Oncolytic Virus Therapies.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing patent details, and other information for emerging Oncolytic Virus Therapies.

Reimbursement Scenario in Oncolytic Virus Therapies

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Oncolytic Virus Therapies domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Oncolytic Virus Therapies market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the Oncolytic Virus Therapies Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 122 million in 2021

Key Companies

Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo

Scope of the Oncolytic Virus Therapies Report

  • The report covers a detailed overview of the development of Oncolytic Virus Therapies across the several selected indications, explaining its various classes, benefits, and challenges for future
  • Comprehensive insight has been provided into the Oncolytic Virus Therapies epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging Oncolytic Virus Therapies is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Oncolytic Virus Therapies market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Oncolytic Virus Therapies market.

Oncolytic Virus Therapies Report Highlights

  • In the coming years, Oncolytic Virus Therapies market is set to change due to improved patient outcomes, treatment of cold tumors, rich emerging pipeline and convenient production and administration; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Oncolytic Virus Therapies R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Oncolytic Virus Therapies. Launch of emerging therapies, will significantly impact the Oncolytic Virus Therapies market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Oncolytic Virus Therapies Report Insights

  • Oncolytic Virus Therapies Patient Population
  • Oncolytic Virus Therapeutic Approaches
  • Oncolytic Virus Therapies Pipeline Analysis
  • Oncolytic Virus Therapies Market Size
  • Oncolytic Virus Therapies Market Trends
  • Oncolytic Virus Therapies Market Opportunities
  • Impact of upcoming Oncolytic Virus Therapies

Oncolytic Virus Therapies Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Oncolytic Virus Therapies Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Oncolytic Virus Therapies Market
  • Oncolytic Virus Drugs Uptake

Oncolytic Virus Therapies Report Assessment

  • Current Treatment Practices
  • Oncolytic Virus Therapies Unmet Needs
  • Oncolytic Virus Therapies Pipeline Product Profiles
  • Oncolytic Virus Therapies Market Attractiveness

Key Questions

Oncolytic Virus Therapies Market Insights:

  • What was the Oncolytic Virus Therapies Market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Oncolytic Virus Therapies total market size as well as market size by therapies across the 7MM during the study period (2019–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Oncolytic Virus Therapies market size during the study period (2019–2032)?
  • At what CAGR, the Oncolytic Virus Therapies market is expected to grow in the 7MM during the study period (2019–2032)?
  • What would be the Oncolytic Virus Therapies market outlook across the 7MM during the study period (2019–2032)?
  • What would be the Oncolytic Virus Therapies market growth till 2032 and what will be the resultant market size in the year 2032?
  • Oncolytic Virus Therapies patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?

 

Oncolytic Virus Therapies Epidemiology Insights:

  • What is the challenges and unmet needs of the Oncolytic Virus Therapies?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Oncolytic Virus Therapies patient pool in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of Oncolytic Virus Therapies in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Oncolytic Virus Therapies?
  • Out of all the 7MM countries, which country would have the highest incident population of Oncolytic Virus Therapies during the study period (2019–2032)?
  • At what CAGR the population is expected to grow by 7MM during the study period (2019–2032)?
  • What are the various recent and upcoming events which are expected to improve the uptake of Oncolytic Virus Therapies?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the marketed Oncolytic Virus Therapies and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing Oncolytic Virus Therapies for the treatment of selected cancers?
  • How many Oncolytic Virus Therapies are in-development by each company for selected cancer treatment?
  • How many are emerging Oncolytic Virus Therapies in mid-stage, and late stage of development for selected cancers treatment?
  • What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Oncolytic Virus Therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Oncolytic Virus Therapies and its status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging Oncolytic Virus Therapies?
  • What are the global historical and forecasted markets of Oncolytic Virus Therapies?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Oncolytic Virus Therapies market
  • To understand the future market competition in the Oncolytic Virus Therapies market and Insightful review of the key unmet needs
  • Organize sales and marketing efforts by identifying the best opportunities for Oncolytic Virus Therapies in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Oncolytic Virus Therapies market
  • To understand the future market competition in the Oncolytic Virus Therapies market

Frequently Asked Questions

What is Oncolytic Virus Cancer?
Oncolytic viruses (OVs), considered an effective anticancer strategy in recent years, are a special type of virus that are naturally or genetically engineered and can replicate preferentially in tumor cells and inhibit tumor growth.
What is the market size for Oncolytic Virus Cancer Therapies in 7MM?
In 2021, the total intratumoral cancer therapies market size was approximately USD 122 million which is expected to rise during the study period (2019–2032).
Which country is expected to account for the most significant prevalent cases for Oncolytic Virus Cancer Therapies in the 7MM?
The US is expected to account for the highest Intratumoral Cancer prevalent cases.
Who are the leading companies in Oncolytic Virus Cancer Therapies Market Landscape?
Some of the leading Oncolytic Virus Cancer companies working in the market are Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo
What are the key strengths of Oncolytic Virus Cancer Therapies Market Report?
Key strengths of Oncolytic Virus Cancer Therapies Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers and Market Barriers.

1. Key Insights

2. Report Introduction

3. Oncolytic Virus Therapies  Market Overview at a Glance

3.1. Market Share (%) Distribution of OVTs in 2019: By Country

3.2. Market Share (%) Distribution of OVTs in 2032: By Country

3.3. Market Share (%) Distribution of OVTs in 2025: By Indication

3.4. Market Share (%) Distribution of OVTs in 2032: By Indication

4. Key Highlights from Oncolytic Virus Therapies Report

5. Executive Summary of Oncolytic Virus Therapies

5.1. Key Events

6. Epidemiology and Market Forecast Flow

7. Background and Overview

7.1. Introduction

7.2. Different types of OVs

7.3. Applications of OVs

7.3.1. Cancer diagnosis

7.3.2. Cancer treatment

7.4. Multiple Mechanisms of Action of OVs for Cancer Therapy

7.4.1. Mechanism of tumor selectivity

7.4.2. Mechanisms of action of viruses destroying cancer cells

7.5. Routes of Administration

7.5.1. Direct intratumoral delivery

7.5.2. IV delivery

7.5.3. Other routes of delivery

7.5.4. Comparing different administration routes

8. Oncolytic Virus Therapies Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale

8.3. Epidemiology Scenario in the 7MM

8.3.1. Total Incident cases of selected cancer types across the 7MM

8.3.2. Target Patient Pool of OVTs by Cancer Types across the 7MM

8.3.3. Treated cases by Cancer types across the 7MM

8.4. Epidemiology Scenario in the US

8.4.1. Total Incident cases of selected cancer types across the US

8.4.2. Target Patient Pool of OVTs by Cancer Types across the US

8.4.3. Treated cases by Cancer Types across the US

8.6. Epidemiology Scenario in EU5

8.6.1. Total Incident cases of selected cancer types across EU5

8.6.2. Target Patient Pool of OVTs by Cancer Types across EU5

8.6.3. Treated cases by Cancer Types across EU5

8.7. Epidemiology Scenario in Japan

8.7.1. Total Incident cases of selected cancer types across Japan

8.7.2. Indication wise target patient pool across Japan

8.7.3. Treated cases by Cancer Types across Japan

9. Key Endpoints in OVTs

10. Marketed therapies

10.1. Key Cross of Marketed Therapies

10.2. IMLYGIC (talimogene laherparepvec): Amgen

10.2.1. Product description

10.2.2. Regulatory milestones

10.2.3. Other developmental activities

10.2.4. Pivotal clinical trial

10.2.5. Ongoing pipeline activity

10.3. DELYTACT (G47Δ): Daiichio Sankyo

10.3.1. Product description

10.3.2. Regulatory milestones

10.3.3. Other developmental activities

10.3.4. Pivotal clinical trials

11. Emerging Therapies

11.1. Key Cross Competition

11.2. ONCOS-102: Targovax

11.2.1. Product description

11.2.2. Other developmental activities

11.2.3. Clinical development

11.2.4. Safety and efficacy

11.3. RP1 (Vusolimogene Oderparepvec): Replimune

11.3.1. Product description

11.3.2. Other developmental activities

11.3.3. Clinical development

11.3.4. Safety and efficacy

11.4. GL-ONC1: Genelux Corporation

11.4.1. Product description

11.4.2. Other developmental activities

11.4.3. Clinical development

11.4.4. Safety and efficacy

11.5. CAN-2409: Candel Therapeutics

11.5.1. Product description

11.5.2. Other Developmental Activities

11.5.3. Clinical development

11.5.4. Safety and efficacy

11.6. DNX-2401 (Tasadenoturev): DNAtrix

11.6.1. Product description

11.6.2. Other developmental activities

11.6.3. Clinical development

11.6.4. Safety and efficacy

11.7. PEXA-VEC (Pexastimogene Devacirepvec; JX-594): SillaJen

11.7.1. Product description

11.7.2. Other developmental activities

11.7.3. Clinical development

11.7.4. Safety and efficacy

11.8. G207: Treovir

11.8.1. Product description

11.8.2. Other developmental activities

11.8.3. Clinical development

11.8.4. Safety and efficacy

11.9. LOAd703: Lokon Pharma AB

11.9.1. Product description

11.9.2. Other developmental activities

11.9.3. Clinical development

11.9.4. Safety and efficacy

11.10. Lerapolturev (Formerly Known as PVSRIPO): Istari Oncology

11.10.1. Product description

11.10.2. Other developmental activities

11.10.3. Clinical development

11.10.4. Safety and efficacy

11.11. CG0070: CG Oncology

11.11.1. Product description

11.11.2. Other developmental activities

11.11.3. Clinical development

11.11.4. Safety and efficacy

12. Attribute Analysis

13. Oncolytic virus therapies: 7 Major Market Analysis

13.1. Key Findings

13.2. Market Outlook

13.3. Market Size of OVTs in the 7MM

13.3.1. Total Market Size of OVTs

13.3.2. Total Market Size of OVTs by Indications in the 7MM

13.3.3. Market Size of OVTs by Therapies

13.4. Market Size of OVTs in the US

13.4.1. Total Market Size of OVTs

13.4.2. Total Market Size of OVTs by Indications

13.4.3. Market Size of OVTs by Therapies in the US

13.5. Market Size of OVTs in EU5

13.5.1. Total Market Size of OVTs

13.5.2. Total Market Size of OVTs by Indications

13.5.3. Market Size of OVTs by Therapies in EU5

13.6. Market Size of OVTs in Japan

13.6.1. Total Market Size of OVTs

13.6.2. Total Market Size of OVTs by Indications

13.6.3. Market Size of OVTs by Therapies in Japan

14. Market Access and Reimbursement

14.1. NICE UK

14.2. IQWiG and GBA Assessment

14.3. Japan

14.4. Patient assistance programs

15. KOL Views

16. SWOT Analysis

17. Unmet Needs

18. Appendix

18.1. Acronyms and Abbreviations

18.2. Bibliography

18.3. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of OVTs

Table 2: Use of OVs for Cancer Diagnosis

Table 3: Administration Routes of OVs in Multiple Tumors

Table 4: Comparison Between Different Administration Methods

Table 5: Incident cases (2020) and Year-over-year (YOY) cancer growth rates

Table 6: Total incident cases of selected cancer types across the 7MM (2019–2032)

Table 7: Target patient Pool of OVTs by Cancer Types across the 7MM (2019–2032)

Table 8: Treated cases by Cancer Types across the 7MM (2019–2032)

Table 9: Total Incident cases of selected cancer types across the US (2019–2032)

Table 10: Target patient Pool of OVTs by Cancer Types across the US (2019–2032)

Table 11: Treated cases by Cancer Types across the US (2019–2032)

Table 12: Total Incident cases of selected cancer types across EU5 (2019–2032)

Table 13: Total Target patient Pool of OVTs by Cancer Types across EU5 (2019–2032)

Table 14: Treated cases by Cancer Types across EU5 (2019–2032)

Table 15: Total Incident cases of selected cancer types in Japan (2019–2032)

Table 16: Target patient Pool of OVTs by Cancer Types in Japan (2019–2032)

Table 17: Treated cases by Cancer Types in Japan (2019–2032)

Table 18: Summary of Results for the ITT Population From IMLYGIC Study 005/05

Table 19: IMLYGIC , Clinical Trial Description, 2022

Table 20: Results on Tumor Reduction Effect and Safety

Table 21: Comparison of emerging drugs under development

Table 22: ONCOS-102; Clinical Trial Description, 2022

Table 23: RP1; Clinical Trial Description, 2022

Table 24: Olvi-Vec; Clinical Trial Description, 2022

Table 25: DNX-2401; Clinical Trial Description, 2022

Table 26: Pexa-Vec (pexastimogene devacirepvec; JX-594), Clinical Trial Description, 2022

Table 27: G207; Clinical Trial Description, 2022

Table 28: LOAd703, Clinical Trial Description, 2022

Table 29: PVSRIPO; Clinical Trial Description, 2022

Table 30: 7MM Market Size of OVTs in USD Million (2019–2032)

Table 31: 7MM Market Size of OVTs By Indications in USD Million (2019–2032)

Table 32: 7MM Market Size of OVTs in USD Million (2019–2032)

Table 33: US Market Size of OVTs in USD Million (2019–2032)

Table 34: US Market Size of OVTs By Indications in USD Million (2019–2032)

Table 35: US Market Size of OVTs in USD Million (2019–2032)

Table 36: EU5 Market Size of OVTs in USD Million (2019–2032)

Table 37: EU5 Market Size of OVTs By Indications in USD Million (2019–2032)

Table 38: EU-5 Market Size of OVTs by Therapies in USD Million (2018–2032)

Table 39: Japan Market Size of OVTs in USD Million (2019–2032)

Table 40: Japan Market Size of OVTs By Indications in USD Million (2019–2032)

Table 41: Japan Market Size of OVTs in USD Million (2019–2032)

Table 42: NICE Assessment for OVT

List of Figures

Figure 1: Milestone of OVTs Development

Figure 2: OVs as Cancer Therapy

Figure 3: The combination of OVTs with Other Therapeutic Approaches

Figure 4: The Multiple Modes of Action of an OV

Figure 5: Virus Targeting Tumor Cells in Various Ways

Figure 6: Mechanism of Anticancer Activity of OVs

Figure 7: Global Heat Map of all cancers in 2020, both sexes, all ages

Figure 8: Total incident cases of selected cancer types across the 7MM (2019–2032)

Figure 9: Target patient Pool of OVTs by Cancer Types across the 7MM (2019–2032)

Figure 10: Treated cases by Cancer Types across the 7MM (2019–2032)

Figure 11: Total Incident cases of selected cancer types across the US (2019–2032)

Figure 12: Target patient Pool of OVTs by Cancer Types across the US (2019–2032)

Figure 13: Treated cases by Cancer Types in the US (2019–2032)

Figure 14: Total Incident cases of selected cancer types in EU5 (2019–2032)

Figure 15: Target patient Pool of OVTs by Cancer Types across EU5 (2019–2032)

Figure 16: Treated cases by Cancer Types across EU5 (2019–2032)

Figure 17: Total Incident cases of selected cancer types in Japan (2019–2032)

Figure 18: Indication wise target patient pool across Japan (2019–2032)

Figure 19: Treated cases by Cancer Types across Japan (2019–2032)

Figure 20: Structure of DNX-2401 (tasadenoturev)

Figure 21: Mode of Action of Pexa-Vec

Figure 22: Market Size of OVTs in the 7MM, USD Million (2019–2032)

Figure 23: Market Size of OVTs By Indications in the 7MM, USD Million (2019–2032)

Figure 24: 7MM Market Size of Oncolytic Virus Therapies in USD Million (2019–2032)

Figure 25: Market Size of OVTs in the US, USD Million (2019–2032)

Figure 26: Market Size of OVTs By Indications in the US, USD Million (2019–2032)

Figure 27: US Market Size of OVTs in USD Million (2019–2032)

Figure 28: Market Size of OVTs in EU5, USD Million (2019–2032)

Figure 29: Market Size of OVTs By Indications in the EU5, USD Million (2019–2032)

Figure 30: EU5 Therapywise market size of OVTs in USD Million (2019–2032)

Figure 31: Market Size of OVTs in Japan, USD Million (2019–2032)

Figure 32: Market Size of OVTs By Indications in Japan, USD Million (2019–2032)

Figure 33: Japan Market Size of OVTs in USD Million (2019–2032)

Targovax
Replimune
Genelux Corporation
Candel Therapeutics
DNAtrix
SillaJen
Treovir
Lokon Pharma AB
Istari Oncology
CG Oncology
Amgen
Daiichio Sankyo

 

Forward to Friend

Need A Quote